2019 STLT Public Health Agency Cancer Cluster Response

Form Approved

OMB No. 0920-0879

Exp. Date 01/31/2021

The Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) are updating "Investigating Suspected Cancer Clusters and Responding to Community Concerns: Guidelines from CDC and the Council of State and Territorial Epidemiologist" (hereafter referred to as the 2013 CDC/CSTE Guidelines; https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6208a1.htm). To help inform the update, CDC/ATSDR is gathering input from subject matter experts and stakeholders, including state, tribal, local, and territorial (STLT) public health agencies.

We recognize that STLT public health agencies use different terms when describing "suspected cancer clusters." For the purposes of this survey, the term "inquiries about excess cancer" refers to inquiries about excess or elevated cancer cases in a particular geographic area possibly linked with an environmental hazard (this includes, but is not limited to, suspected cancer clusters). The goal of this survey is to gather input from STLT public health agencies about how they address community concerns about excess cancer, available and needed resources, and barriers, facilitators, and best practices for effectively responding to community concerns.

The survey, which may take approximately 30 minutes to complete, is intended to be completed by an individual who is familiar with the agency's process for responding to inquiries about excess cancer. Participation is voluntary and responses to all questions will be kept secure to the fullest extent allowed by law. Aggregate information gathered from this survey may be included in the updated Guidelines document and/or published separately. CDC/ATSDR will only release information in aggregate form and will ensure that no individual or public health agency is identifiable.

Thank you in advance for your participation. We kindly request that you complete this assessment by INSERT DATE. If you have any questions or would like to provide additional input into the Guidelines update, please contact us at CCGuidelines@cdc.gov

CDC estimates the average public reporting burden for this collection of information as 30 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-0879)



Agency Information
Which type of jurisdiction is your public health agency affiliated with?
 ○ Federal ○ State ○ Territory ○ City or County (Local) ○ Tribe or Tribal Epidemiology Center ○ Other
If other, please type in type of jurisdiction
What is the name of your agency? (do not abbreviate)
What is your title? (do not abbreviate)
What is your role within the agency as it relates to addressing inquiries about excess cancer? Epidemiologist
If other, please specify what role is
Is your public health agency responsible for responding to inquiries about excess cancer? Or Yes, my agency responds to inquires when they are received Or No, my agency refers inquiries to another agency or organization (e.g., state health department) Or Don't know
What agency or organization do you refer inquiries to?



6

7

Is there someone else in your agency who would be better suited to complete this survey?
Yes. If so please, forward this to the appropriate individual.No
Over the past 7 years, has your public health agency recieved one or more inquiries about excess cancer?
YesNoDon't Know
About how many inquiries about excess cancer does your public health agency receive each year?
 ☐ 1-5 ☐ 6-10 ☐ 11-25 ☐ >26 ☐ Don't Know

Guidle	eines	and	Prot	ocol	ls
--------	-------	-----	------	------	----

3	Is your public health agency familiar with the 2013 CDC/CSTE Guidelines for "Investigating Suspected Cancer Clusters and Responding to Community Concerns"?
	 ○ Very familiar with the Guidelines ○ Somewhat familiar with the Guidelines ○ Have heard of the Guidelines, but have not read them ○ Have NOT heard of the Guidelines ○ Don't Know
9	Please rate the usefulness of the 2013 CDC/CSTE Guidelines
	 Extremely useful Very useful Moderately useful Slightly useful Not at all useful Don't know
10	Does your public health agency have a written protocol for addressing inquiries about excess cancer?
	YesNoDon't Know
11	If you are willing to share a copy of your agency's protocol with CDC, please upload here.
12	Is your public health agency's protocol consistent with the 2013 CDC/CSTE Guidelines?
	 Yes, our agency uses the 2013 Guidelines without modification Yes, our agency protocol is consistent with the 2013 Guidelines with some modification No, our agency protocol is not consistent with the 2013 CDC/CSTE Guidelines Don't Know
13	Does your public health agency use the term "cluster" when addressing community concerns about elevated cancer rates in a specific geographic area?
	YesNoDon't Know
14	What term(s) does your agency use?
15	The 2013 CDC/CSTE Guidelines define a cancer cluster as "a greater than expected number of cancer cases that occurs within a group of people in a geographic area over a defined period of time." Do you think this definition of a cancer cluster should be revised in the updated guidelines?
	 Yes, the definition should be revised No, the definition should remain the same Don't Know, I'm not familiar with the cancer cluster definition
16	How should the definition of cancer clusters be revised?

17	The 2013 CDC/CSTE Guidelines recommend a four-step approach to addressing cancer cluster inquiries. Should the four-step approach be revised in the updated guidelines?
	 Yes, the four-step approach should be revised No, the four-step approach should remain the same Neutral Don't Know, I'm not familiar with the approach in the Guidelines
18	How should the approach be revised?
10	
19	How helpful would it be to your public health agency if CDC/ATSDR broadened the scope of the updated guidelines to more broadly address community concerns about "cancer and environmental hazards" rather than focusing on "suspected cancer clusters"?
	 ○ Very helpful ○ Somewhat helpful ○ Not helpful ○ Don't Know

Public Health Agency Response Activities
Does your public health agency have a tracking system in place to record or log inquiries about excess cancer?
YesNoDon't Know
How many inquiries about excess cancer did your public health agency receive in 2019? (Please use data from your agency's tracking system, if one exists. Otherwise, please estimate the number of inquiries received.)
(Please indicate if not known or if not tracked and unable to estimate)
The number provided above is:
○ Actual/measure○ Estimated
When considering all the inquiries your agency received in 2019, please select the source(s) of these inquiries.
(Check all that apply)
☐ Individual Resident ☐ Community or Advocacy Group ☐ Physician/Health Care Provider ☐ Local Health Department ☐ State Cancer Registry ☐ Other State Agency ☐ Federal Agency ☐ Elected Official ☐ News Media ☐ Other
Individual Resident: Number of inquiries?
(Please note that the total numbers for all sources checked should add up to the response provided in Question 21
Community or Advocacy Group: Number of inquiries?
(Please note that the total numbers for all sources checked should add up to the response provided in Question 21
Physician/Health Care Provider: Number of inquiries?
(Please note that the total numbers for all sources checked should add up to the response provided in Question 21

(Please note that the total numbers for all sources checked should add up to the response provided in Question 21)

₹EDCap°

State Cancer Registry: Number of inquiries?
(Please note that the total numbers for all sources checked should add up to the response provided in Question 21)
Other State Agency: Number of inquiries?
(Please note that the total numbers for all sources checked should add up to the response provided in Question 21)
Federal Agency: Number of inquiries?
(Please note that the total numbers for all sources checked should add up to the response provided in Question 21)
Elected Official: Number of inquiries?
(Please note that the total numbers for all sources checked should add up to the response provided in Question 21)
News Media: Number of inquiries?
(Please note that the total numbers for all sources checked should add up to the response provided in Question 21)
Other: Name source(s) and provide number of inquiries?
(Please note that the total numbers for all sources checked should add up to the response provided in Question 21)



24. When considering all the inquiries your agency received in 2019, please tell us how often did your agency carry out the following activities.

did your agency carry out t	Never or Almost Never (>10%)	Rarely (10-40%)	Sometimes (40-60%)	Often (60-90%)	Always or Almost Always (90-100%)	Not Applicable
Respond to email/phone inquiry	\bigcirc	\bigcirc	\circ	\bigcirc	\circ	\circ
Provide education during initial email/phone contact	0	0	0	\circ	0	0
Contact state health department (if applicable)	0	0	0	\circ	0	0
Analyze cancer registry data to determine whether there is an elevated rate of cancer in the community of concern (e.g., calculate an SIR)	0	0	0	0	0	0
Collect additional information about cases, such as potential exposures and risk factors (e.g., conduct case series study or case reports)	0	0	0	0	0	0
Conduct a case-control study	\circ	\circ	\circ	\bigcirc	\circ	\circ
Review environmental data	\circ	\bigcirc	\circ	\bigcirc	\circ	\circ
Conduct environmental sampling	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\circ
Contact federal agency for technical assistance	0	0	0	0	\bigcirc	0
Contact non-governmental organization, (e.g. academia, local medical community, clinician, Pediatric Environmental Health Specialty Units/PEHSU) for assistance	0	0	0	0	0	0
Create public communication product (e.g. web, printed materials, social media)	0	0	0	0	0	0
Release information through news media	0	0	0	0	0	0
Hold community meeting(s)	\circ	\circ	\bigcirc	\circ	\circ	\bigcirc
Establish a Community Advisory Panel	0	0	0	0	0	0
Prepare written report for public dissemination	0	0	0	0	0	0

If any, please list other activities not listed above that your agency may conduct:

(Additionally please indicate how often each activity is conducted using the scale in the previous question)

₹EDCap°

25	Does your agency routinely conduct follow-up activities on previous inquiries (e.g., follow-up communication, recalculate cancer statistics on a recurring basis, etc.)?
	YesNoDon't Know
26	In 2019, how many inquiries from previous years did your agency conduct follow-up activities for?
	(Indicate if not known, or not tracked)
27	To more fully understand your agency's approach, CDC/ATSDR would like to review example reports or documents that highlight how your agency responds to inquiries about excess cancer. If you are willing to share any documents, please upload.
28	Does your public health agency use geospatial software and methods when addressing inquiries about excess cancer (for example, to assess whether there is an elevated number of cancer cases in a particular location and time)? Ores Ores Don't Know
29	If no, why not?
	 ☐ Geospatial methods are not part of the 2013 CDC/CSTE Guidelines ☐ Do not have trained staff ☐ Software too expensive ☐ Do not receive many inquiries ☐ Other
	If other, please write in here.
30	Does your public health agency analyze cancer incidence data on a routine basis to proactively look for geographic areas with elevated cancer rates?
	YesNoDon't Know
31	Does your jurisdiction have a CDC-funded Environmental Public Health Tracking program? For more information see: http://ephtracking.cdc.gov/showHome.action O Yes O No O Don't know



32	cancer) coordinate with the CDC-funded Environmental Public Health Tracking program?
	 Yes, they are part of the same program Yes, the programs coordinate but they are separate programs No Don't know
33	How does the Environmental Public Health Tracking program contribute to your agency's ability to respond to inquiries about excess cancer?
	(If a tracking program exists but does not contribute to this work, please indicate so in box)
34	Does your jurisdiction have an ATSDR-funded APPLETREE (ATSDR's Partnership to Promote Localized Efforts to Reduce Environmental Exposure) program? For more information see: https://www.atsdr.cdc.gov/states/index.html
	○ Yes ○ No
	O Don't Know
35	Does the program/team that responds to inquiries about excess cancer (and conducts investigations into excess cancer) coordinate with the ATSDR-funded APPLETREE program?
	Yes, they are part of the same programYes, the programs coordinate but they are separate programs
	○ No ○ Don't Know
36	How does the APPLETREE program contribute to your agency's ability to respond to inquiries about excess cancer?
	(if program exists, but does not contribute please indicate so in hox)

Communication with the Public

37	Does your public health agency have a written protocol for how to communicate with the public regarding potential cancer clusters?
	 Yes, as a separate document specific to cancer cluster communications Yes, as part of the agency's protocol for addressing inquiries about excess cancer No Don't know
38	If you are willing to share a copy of your agency's protocol with CDC, please upload here.
	(This refers to the protocol in Question 37)
39	Is your public health agency familiar with the Cancer Cluster Communication Toolkit developed by CDC and the National Public Health Information Center? (available at: https://www.nphic.org/toolkits/cancer-cluster)
	 Very familiar with the Communications Toolkit Somewhat familiar with the Communications Toolkit Have heard of the Communications Toolkit, but have not read it (or am not familiar with it) Have NOT heard of the Communications Toolkit Don't know
40	Please rate the usefulness of the Communications Toolkit.
	 Extremely useful Very useful Moderately useful Slightly useful Not at all useful Don't know
41	CDC/ATSDR is interested in receiving input on the current and updated guidelines from community members and advocacy groups. Please provide the name of individuals or advocacy groups that you believe might be helpful in obtaining such input.
	(If none, please respond N/A)

₹EDCap°

42	Approximately how many people in your public health agency are involved in responding to inquiries about excess cancer on a routine basis? (Number of people)
	(If not known, please write in "Don't Know")
43	For each person involved in responding to inquiries about excess cancer, please provide the following information: Estimates percent time spent addressing these inquires in the past year (note that 100% is equal to 40 hrs/wk) Job Title or Discipline (e.g., Epidemiologist, Health Communicator, Statistician, Environmental Health Scientist, GIS analyst) Agency/Department/Organization (e.g., Health Department, Cancer Registry, Environmental Protection) (Provide information for EACH person. Example: Individual 1, Individual 2, etc.)
44	Does your public health agency have health communicators trained specifically on how to address inquiries about excess cancer?
	YesNoDon't Know
45	Does your public health agency have personnel trained in geospatial analysis who are available to assist with addressing inquiries about excess cancer?
	YesNoDon't Know



cancer? (If not known, What are the transport cancer? (If not known, What communicancer? (If not known,	top 3 barriers (i.e., factors that limit or restrict) for effectively addressing inquiries about excess , please write in "Don't Know") top 3 facilitators (i.e., factors that promote or help) for effectively addressing inquiries about excess , please write in "Don't Know") nication resources would improve your agency's ability to effectively address inquiries about excess , please write in "Don't Know")	
What are the cancer? (If not known, What communicancer? (If not known,	top 3 facilitators (i.e., factors that promote or help) for effectively addressing inquiries about excess , please write in "Don't Know") nication resources would improve your agency's ability to effectively address inquiries about excess	
cancer? (If not known, What communicancer? (If not known,	nication resources would improve your agency's ability to effectively address inquiries about excess	
cancer? (If not known, What communicancer? (If not known,	nication resources would improve your agency's ability to effectively address inquiries about excess	
What communicancer? (If not known,	nication resources would improve your agency's ability to effectively address inquiries about excess	
cancer? (If not known, What scientific		
What scientific	, please write in "Don't Know")	
What scientific or technical resources would improve your agency's ability to effectively address inquiries about excess cancer?		
(If not known,	, please write in "Don't Know")	
What type of I	Federal governmental assistance would your public health agency find most useful?	
(If not known,	, please write in "Don't Know")	



Best Practices and Recommendations	for Updated	Guidelines
------------------------------------	-------------	-------------------

51	Has your public health agency ever formally evaluated any aspect (e.g., risk communication and education) of your agency's approach to addressing inquiries about excess cancer?
	YesNoDon't Know
52	If you are willing to share the finding of your evaluation, please upload here.
53	What are best practices for communicating with the public about inquiries about excess cancer?
	(If not known, please write in "Don't Know")
54	What are best practices for assessing and investigating inquiries about excess cancer?
	(If not known, please write in "Don't Know")
55	Please use this space to provide any additional information or comments you would like to share with CDC/ATSDR.

